# Serum Extracellular Vesicle-Associated GULP1 Is a Key Indicator of Hepatocellular Carcinoma

**Authors:** Hyung Seok Kim, Ju A Son, Minji Kang, Soon Sun Kim, Geum Ok Baek, Moon Gyeong Yoon, Se Ha Jang, Dokyung Jung, Ji Eun Han, Jae Youn Cheong, Jung Woo Eun

PMC · DOI: 10.32604/or.2025.070392 · Oncology Research · 2026-01-19

## TL;DR

This study identifies a new noninvasive biomarker, EV-GULP1, that improves early detection and prognosis of hepatocellular carcinoma compared to the current standard.

## Contribution

EV-GULP1 is introduced as a novel, noninvasive biomarker for HCC detection and prognosis.

## Key findings

- EV-GULP1 expression is significantly higher in HCC patients, including early-stage cases.
- EV-GULP1 outperforms AFP in diagnostic accuracy with an AUC of 0.919.
- High EV-GULP1 levels correlate with worse survival outcomes in HCC patients.

## Abstract

Early detection of hepatocellular carcinoma (HCC) is a significant challenge due to the limited sensitivity of alpha-fetoprotein (AFP). This study aimed to assess serum-derived extracellular vesicle-encapsulated GULP PTB domain-containing engulfment adaptor 1 (EV-GULP1) as a novel, noninvasive biomarker for HCC detection and prognosis, leveraging the potential of tumor-specific molecules carried by small extracellular vesicles (EVs).

The study utilized both internal and external cohorts of HCC patients and controls. Small EVs were isolated from serum samples, then characterized and validated to confirm their identity. The expression levels of EV-GULP1 were quantified using quantitative reverse transcription polymerase chain reaction (qRT-PCR).

EV-GULP1 expression was found to be significantly higher in HCC patients, including those with early-stage disease, when compared to control groups. It demonstrated superior diagnostic accuracy over AFP, achieving an area under the curve (AUC) of 0.919, and was particularly effective in detecting AFP-negative cases. Furthermore, high EV-GULP1 expression correlated with worse overall and disease-free survival outcomes.

These findings highlight EV-GULP1 as a highly promising noninvasive biomarker for hepatocellular carcinoma. It offers improved diagnostic accuracy for early detection and better risk stratification for prognosis compared to the current standard, AFP.

## Linked entities

- **Genes:** GULP1 (GULP PTB domain containing engulfment adaptor 1) [NCBI Gene 51454]
- **Diseases:** hepatocellular carcinoma (MONDO:0007256), HCC (MONDO:0007256)

## Full-text entities

- **Genes:** AFP (alpha fetoprotein) [NCBI Gene 174] {aka AFPD, FETA, HPAFP}, GULP1 (GULP PTB domain containing engulfment adaptor 1) [NCBI Gene 51454] {aka CED-6, CED6, GULP}
- **Diseases:** HCC (MESH:D006528), tumor (MESH:D009369)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12848681/full.md

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12848681/full.md

## References

42 references — full list in the complete paper: https://tomesphere.com/paper/PMC12848681/full.md

---
Source: https://tomesphere.com/paper/PMC12848681